RSLS_OUT_1 [2025-04-24 04:29:30 -0400] 6604 Bytes | 1816 tokens | Cum: 1816 tkns (22.70% of 8k)
==========================================================================

We are in the 'Lightning Round' baby! It's 4:29 AM on Thu Apr 24, 2025, and I'm firing up the spotlight on ReShape Lifesciences (RSLS), moving from $0.3832 to $0.3994. Is this a can’t-miss rocket or a one-hit wonder? Let’s dissect the numbers!

--- COMPANY PROFILE ---
Company: ReShape Lifesciences (RSLS)
IPO: 2021-06-16 (3 Years Ago)
Market Cap: $5,255,088
Shares Outstanding: 3,310,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: Reshape Lifesciences Inc is a medical device company focused on technologies to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus.

Here’s a list of headlines for ReShape Lifesciences:

Apr-21-25 08:31AM - ReShape Lifesciences Receives Notice of Allowance for Additional U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology
Apr-10-25 05:54PM - ReShape Lifesciences Inc. (RSLS) Earnings Highlights and Strategic Business Update Conference (Transcript)
Apr-09-25 04:05PM - ReShape Lifesciences Partners with Motion Informatics to Bring AI-Driven Neurorehabilitation Technology to the U.S. Market
Apr-07-25 04:05PM - ReShape Lifesciences Reports Year Ended December 31, 2024 Financial Results and Provides Corporate Update
Mar-10-25 08:31AM - ReShape Lifesciences Receives Notice of Allowance for U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology
Feb-25-25 08:31AM - ReShape Lifesciences Signs Distribution Agreement in Canada With Liaison Medical for its Next-Generation Lap-Band 2.0 FLEX
Feb-15-25 11:17PM - ReShape Lifesciences Announces Pricing of Upsized $6.0 Million Public Offering
Feb-03-25 08:31AM - ReShape Lifesciences Granted Key International Patent in Israel for Its Proprietary Diabetes Neuromodulation Technology
Jan-13-25 08:31AM - ReShape Lifesciences Provides Update on Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys
Nov-14-24 04:05PM - ReShape Lifesciences Reports Third Quarter Ended September 30, 2024 Financial Results and Provides Corporate Update
Nov-12-24 04:05PM - ReShape Lifesciences to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update
Nov-12-24 04:05PM 08:31AM - ReShape Lifesciences Receives Health Canada Approval for its Next-Generation Lap-Band 2.0 FLEX
Nov-11-24 08:31AM - ReShape Lifesciences Receives NIH Supplementary Grant with the University of Southern California's Center for Autonomic Nerve Recording and Stimulation Systems (CARSS) to Further Develop Next-Generation Electrodes for ReShape's Proprietary Diabetes Bloc-Stim Neuromodulation Technology
Sep-23-24 09:48AM - Upcoming Stock Splits This Week (September 23 to September 27) Stay Invested
Sep-19-24 08:31AM - ReShape Lifesciences Announces 1-for-58 Reverse Stock Split
Aug-14-24 04:05PM - ReShape Lifesciences Reports Second Quarter Ended June 30, 2024 Financial Results and Provides Corporate Update
Aug-13-24 08:31AM - ReShape Lifesciences to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update
Jul-09-24 12:13PM - Vyome to go public and trade on the Nasdaq Capital Market under the ticker symbol HIND
Jul-09-24 12:13PM 08:31AM - ReShape Lifesciences Enters Into Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys
May-29-24 07:56AM - Why Is Reshape Lifesciences (RSLS) Stock Up 80% Today?
May-29-24 07:56AM 07:39AM - Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
May-19-24 08:09AM - ReShape Lifesciences Inc. (NASDAQ:RSLS) Q1 2024 Earnings Call Transcript

Prior AI Reports for RSLS:
1. 2025-04-04 – Score: 18 – Target: 0.5131 – Highs: 0.7151 / 0.6210 / 0.48
severe-underperformance-and-high-short-interest-cloud-companys-future
2. 2025-04-01 – Score: 20 – Target: 0.8455 – Highs: 3.0500 / 0.7018 / 0.43
struggling-company-sees-glimmer-of-hope-amid-sales-growth

(Note: Highs = Same day / 2nd day / 3rd day)

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2025-04-10T09:43:21Z - US Stocks Likely To Open Lower Ahead Of March Inflation Release: Expert Highlights 'Fairly Weak Returns' After 5%+ Gains In S&P 500
B2 - 2025-03-23T22:59:00Z - SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FNA, AVTE, RSLS on Behalf of Shareholders
B3 - 2025-02-16T04:17:00Z - ReShape Lifesciences® Announces Pricing of Upsized $6.0 Million Public Offering
B4 - 2025-01-13T13:31:00Z - ReShape Lifesciences® Provides Update on Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys
B5 - 2024-07-09T12:32:57Z - ReShape Lifesciences® Enters Into Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With ... - GlobeNewswire
B6 - 2024-05-30T10:54:00Z - Investing in AI Penny Stocks? 3 Top Tips

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for ReShape Lifesciences (RSLS).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

RSLS_OUT_3 [2025-04-24 04:29:31 -0400] 803 Bytes | 223 tokens | Cum: 2041 tkns (25.51% of 8k)
==========================================================================

Showing B3 (chunk 1 of 1): B3:
**ReShape Lifesciences® Announces Pricing of Upsized $6.0 Million Public Offering**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/02/16/3026963/0/en/ReShape-Lifesciences-Announces-Pricing-of-Upsized-6-0-Million-Public-Offering.htmlReShape Lifesciences, a weight loss and metabolic health solutions company, announced the pricing of its public offering of 2,575,107 units at $2.33 per unit. The offering is expected to raise approximately $6.0 million in gross proceeds.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

RSLS_OUT_5 [2025-04-24 04:29:32 -0400] 1033 Bytes | 302 tokens | Cum: 2345 tkns (29.31% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-22T03:16:09Z - ReShape Lifesciences Ignites Retail Frenzy As Stock Soars On US Patent For Diabetes Neuromodulation ...
A2 - 2025-04-22T01:31:00Z - ReShape Gets USPTO Nod For Energy-Efficient Diabetes Neuromodulation Patent Using VBloc Tech...
A3 - 2025-04-21T17:05:41Z - 12 Health Care Stocks Moving In Monday's Intraday Session - Annovis Bio (NYSE:ANVS), Adagio Medical ...
A4 - 2025-04-21T12:59:56Z - ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to Its Proprie...
A5 - 2025-04-21T12:51:49Z - ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to Its Proprie...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

RSLS_OUT_7 [2025-04-24 04:29:33 -0400] 1181 Bytes | 307 tokens | Cum: 2654 tkns (33.17% of 8k)
==========================================================================

Showing A1 (chunk 1 of 3): A1:
**ReShape Lifesciences Ignites Retail Frenzy As Stock Soars On US Patent For Diabetes Neuromodulation System By Stocktwits**Date: 2025-04-22Source: {'uri': 'in.investing.com', 'dataType': 'news', 'title': 'Investing.com India'}URL: https://in.investing.com/news/stock-market-news/reshape-lifesciences-ignites-retail-frenzy-as-stock-soars-on-us-patent-for-diabetes-neuromodulation-system-4782988Stocktwits - Shares of ReShape Lifesciences Inc. rose over 23% on Monday and extended gains after the bell, driven by the medical device company securing a key patent.

The Irvine, California-based company said it had received a Notice of Allowance from the U.S. Patent and Trademark Office for its patent application titled "High-Frequency Low Duty Cycle Patterns for Neural Regulation."

The patent, which will provide protection through August 2037, supports the company's Diabetes Neuromodulation s

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

RSLS_OUT_9 [2025-04-24 04:29:33 -0400] 1181 Bytes | 267 tokens | Cum: 2923 tkns (36.54% of 8k)
==========================================================================

Showing A1 (chunk 2 of 3): ystem.

The technology leverages ReShape's proprietary vagus nerve block and stimulation platform to regulate blood glucose in patients with Type 2 diabetes by modulating nerve signals to the liver and pancreas.

The newly patented algorithm delivers short bursts of high-frequency stimulation with micro- and millisecond pauses, offering a more energy-efficient alternative to continuous stimulation.

ReShape said this innovation uses approximately 10 times less energy than traditional continuous signals, enabling smaller devices and longer battery life.

The announcement sent 24-hour message volume for ReShape on Stocktwits spiking by more than 7,300% on Monday, with sentiment turning 'neutral' from 'bearish' a day ago.

RSLS sentiment and message volume as of April 21. | source: StocktwitsOne bullish user posted that ReShape stock "is a long hold for me, $2.5+ target."

Another user ackn

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

RSLS_OUT_11 [2025-04-24 04:29:34 -0400] 594 Bytes | 163 tokens | Cum: 3088 tkns (38.60% of 8k)
==========================================================================

Showing A1 (chunk 3 of 3): owledged the day's news but speculated that a "mega-merger run" from ReShape's proposed reverse merger with Vyome Therapeutics was coming.

ReShape's stock has seen its short interest rise from 4.2% to 6.1% this year, according to Koyfin data.

Shares of the company have lost over 91% of their value this year.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

RSLS_OUT_13 [2025-04-24 04:29:35 -0400] 1076 Bytes | 297 tokens | Cum: 3387 tkns (42.34% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-04-21 8-K Item 1.01 Entry into a Material Definitive Agrmt.

On April 15, 2025, ReShape Lifesciences Inc. (ReShape) and Vyome Therapeutics, Inc. (Vyome) entered into a promissory note pursuant to which ReShape agreed to loan up to $400,000 to Vyome in three tranches through no later t...

S2 - 2025-04-04 10-K ITEM 7. MGT DISC & ANALYSIS OF FIN COND & RESULTS OF OPER

Except for the historical information contained herein, the matters discussed in this Mgts Discussion and Analysis of Fin Cond and Results of Oper, and elsewher...

S3 - 2025-02-20 8-K Item 1.01 Entry into a Material Definitive Agrmt.

On February 15, 2025, ReShape Lifesciences Inc. (the Company) entered into a Securities Purchase Agrmt (the Purchase Agrmt) with certain investors (the Investors) pursuant to which the Company agreed to issue and sel...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

RSLS_OUT_15 [2025-04-24 04:29:36 -0400] 1181 Bytes | 300 tokens | Cum: 3689 tkns (46.11% of 8k)
==========================================================================

Showing S1 (chunk 1 of 3): S1:
Item 1.01 Entry into a Material Definitive Agreement.

On April 15, 2025, ReShape Lifesciences Inc. (ReShape) and Vyome Therapeutics, Inc. (Vyome) entered into a promissory note pursuant to which ReShape agreed to loan up to $400,000 to Vyome in three tranches through no later than May 15, 2025. Vyome will use the proceeds for working capital purposes as well as legal, accounting and other expenses related to the transactions contemplated by the Agreement and Plan of Merger, dated July 8, 2024, between the parties (the Merger Agreement). The outstanding principal balance under the promissory note will bear interest at the rate of 8.0% per annum. If the Merger Agreement is terminated by ReShape under Section 8.01(b)(iv) thereof (because the Concurrent Financing Agreement (as defined in the Merger Agreement) is not in full force and effect such that the Concurrent Financing shall not

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

RSLS_OUT_17 [2025-04-24 04:29:37 -0400] 1181 Bytes | 274 tokens | Cum: 3965 tkns (49.56% of 8k)
==========================================================================

Showing S1 (chunk 2 of 3): be consummated immediately following the effective time of the merger without the further satisfaction of any conditions) then the promissory note will become senior in right of payment to all other debt of Vyome and will become a secured obligation of Vyome. The aggregate unpaid principal amount under the promissory note and all accrued unpaid interest will be due and payable on September 30, 2025. If the merger is completed prior to September 30, 2025, then Vyome will not be required to repay the amounts outstanding under the promissory note, but the aggregate amount of unpaid principal and interest will then be counted as ReShape net cash under the Merger Agreement.

In connection with the promissory note, ReShape and Vyome also agreed to extend the date after which either party could terminate the Merger Agreement from March 31, 2025 to June 30, 2025.

The foregoing description of th

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

RSLS_OUT_19 [2025-04-24 04:29:38 -0400] 526 Bytes | 139 tokens | Cum: 4106 tkns (51.32% of 8k)
==========================================================================

Showing S1 (chunk 3 of 3): e promissory note does not purport to be complete and is qualified in its entirety by reference to the full text of the promissory note, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference....

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

RSLS_OUT_21 [2025-04-24 04:29:44 -0400] 5945 Bytes | 1592 tokens | Cum: 5702 tkns (71.28% of 8k)
==========================================================================

This is our set of metrics for ReShape Lifesciences.
Please analyze the numbers.

+--------------------+-----------------------+------------------------+-----------------------+
| Volume: 3,561,817 | Perf Month: -39.81% | Option/Short: No / Yes | Sales Y/Y TTM: -7.74% |
+--------------------+-----------------------+------------------------+-----------------------+
| Avg Volume: 15.59M | Perf Quarter: -90.95% | Short Float: 7.45% | ROE: -222.46% |
+--------------------+-----------------------+------------------------+-----------------------+
| Rel Volume: 0.22 | Index: - | Short Ratio: 0.04 | ROI: - |
+--------------------+-----------------------+------------------------+-----------------------+
| RSI (14): 42.76 | Market Cap: 4.40M | Short Interest: 0.69M | Sales Surprise: - |
+--------------------+-----------------------+------------------------+-----------------------+
| ATR (14): 0.21 | Shs Outstand: 11.28M | Beta: 1.39 | EPS Surprise: - |
+--------------------+-----------------------+------------------------+-----------------------+
| SMA20: -16.47% | Shs Float: 9.24M | Sales Q/Q: -8.93% | P/E: - |
+--------------------+-----------------------+------------------------+-----------------------+
| SMA50: -54.69% | Inst Own: 0.30% | Sales past 5Y: 43.37% | Earnings: Nov 14 AMC |
+--------------------+-----------------------+------------------------+-----------------------+
| SMA200: -92.86% | Insider Own: 18.08% | Employees: 18 | |
+--------------------+-----------------------+------------------------+-----------------------+
| Perf Week: 2.63% | Insider Trans: 0.00% | Debt/Eq: - | |
+--------------------+-----------------------+------------------------+-----------------------+

The next section covers any insider trading by ReShape Lifesciences officers or majority shareholders (if available).

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 2292000.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -1581000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 0.39
Average Volume: 42744792.0
30-Day High: 1.59
30-Day Low: 0.3097

[Detailed Financials: Q3 2024]
- Total Assets: $5,615,000.00
- Total Liabilities: $4,128,000.00
- Total Equity: $1,487,000.00
- Current Assets: $5,338,000.00
- Current Liabilities: $4,025,000.00

[Income Statement: Q3 2024]
- Revenue: $2,292,000.00
- Net Income: $-1,581,000.00
- Gross Profit: $1,439,000.00
- Operating Income: $-1,761,000.00
- Earnings Per Share (EPS): -3.11

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $0.00

[Detailed Financials: Q2 2024]
- Total Assets: $6,393,000.00
- Total Liabilities: $3,358,000.00
- Total Equity: $3,035,000.00
- Current Assets: $6,087,000.00
- Current Liabilities: $3,201,000.00

[Income Statement: Q2 2024]
- Revenue: $1,965,000.00
- Net Income: $-1,595,000.00
- Gross Profit: $1,134,000.00
- Operating Income: $-2,054,000.00
- Earnings Per Share (EPS): -0.06

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $2,072,000.00
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of ReShape Lifesciences (RSLS).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about ReShape Lifesciences.

2) MARKET_SCORE[]
This conversation was initiated because RSLS is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for RSLS.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, RSLS could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect RSLS to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of ReShape Lifesciences.

11) ETHICAL_RATING[]
Rate ReShape Lifesciences’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of ReShape Lifesciences.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

RSLS_IN_23 [2025-04-24 04:29:45 -0400] 126 Bytes | 29 tokens | Cum: 5917 tkns (73.96% of 8k)
==========================================================================

====================================
[2025-04-24 04:29:45] # Analysis Completed
Elapsed Time: 14.88 seconds